1. Theranostics Using MCM-41-Based Mesoporous Silica Nanoparticles: Integrating Magnetic Resonance Imaging and Novel Chemotherapy for Breast Cancer Treatment.
- Author
-
Pires ICB, Shuchi SI, Tostes BVA, Santos DKDDN, Burnett WL, Leonce BC, Harvey OR, Coffer JL, de Sousa Filho IA, de Athayde-Filho PF, Junior SA, and Mathis JM
- Subjects
- Animals, Humans, Female, Mice, Cell Line, Tumor, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Antineoplastic Agents therapeutic use, Contrast Media chemistry, Gadolinium chemistry, Porosity, Xenograft Model Antitumor Assays, Silicon Dioxide chemistry, Breast Neoplasms drug therapy, Breast Neoplasms diagnostic imaging, Breast Neoplasms pathology, Theranostic Nanomedicine methods, Magnetic Resonance Imaging methods, Nanoparticles chemistry
- Abstract
Advanced breast cancer remains a significant oncological challenge, requiring new approaches to improve clinical outcomes. This study investigated an innovative theranostic agent using the MCM-41-NH
2 -DTPA-Gd3 ⁺-MIH nanomaterial, which combined MRI imaging for detection and a novel chemotherapy agent (MIH 2.4Bl) for treatment. The nanomaterial was based on the mesoporous silica type, MCM-41, and was optimized for drug delivery via functionalization with amine groups and conjugation with DTPA and complexation with Gd3+ . MRI sensitivity was enhanced by using gadolinium-based contrast agents, which are crucial in identifying early neoplastic lesions. MIH 2.4Bl, with its unique mesoionic structure, allows effective interactions with biomolecules that facilitate its intracellular antitumoral activity. Physicochemical characterization confirmed the nanomaterial synthesis and effective drug incorporation, with 15% of MIH 2.4Bl being adsorbed. Drug release assays indicated that approximately 50% was released within 8 h. MRI phantom studies demonstrated the superior imaging capability of the nanomaterial, with a relaxivity significantly higher than that of the commercial agent Magnevist. In vitro cellular cytotoxicity assays, the effectiveness of the nanomaterial in killing MDA-MB-231 breast cancer cells was demonstrated at an EC50 concentration of 12.6 mg/mL compared to an EC50 concentration of 68.9 mg/mL in normal human mammary epithelial cells (HMECs). In vivo, MRI evaluation in a 4T1 syngeneic mouse model confirmed its efficacy as a contrast agent. This study highlighted the theranostic capabilities of MCM-41-NH2 -DTPA-Gd3 ⁺-MIH and its potential to enhance breast cancer management.- Published
- 2024
- Full Text
- View/download PDF